Morse, M. A., Hobeika, A., Gwin, W., Osada, T., Gelles, J., Rushing, C., … Lyerly, H. K. (2015). Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients. Journal for Immunotherapy of Cancer, 3(Suppl 2), P444–P444. https://doi.org/10.1186/2051-1426-3-s2-p444

Morse, Michael A., Amy Hobeika, William Gwin, Takuya Osada, Jonathan Gelles, Christel Rushing, Donna Niedzwiecki, and H Kim Lyerly. “Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients.” Journal for Immunotherapy of Cancer 3, no. Suppl 2 (January 2015): P444–P444. https://doi.org/10.1186/2051-1426-3-s2-p444.

Morse MA, Hobeika A, Gwin W, Osada T, Gelles J, Rushing C, et al. Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients. Journal for immunotherapy of cancer. 2015 Jan;3(Suppl 2):P444–P444.

Morse, Michael A., et al. “Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients.” Journal for Immunotherapy of Cancer, vol. 3, no. Suppl 2, Jan. 2015, pp. P444–P444. Epmc, doi:10.1186/2051-1426-3-s2-p444.

Morse MA, Hobeika A, Gwin W, Osada T, Gelles J, Rushing C, Niedzwiecki D, Lyerly HK. Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients. Journal for immunotherapy of cancer. 2015 Jan;3(Suppl 2):P444–P444.